期刊
HUMAN MOLECULAR GENETICS
卷 31, 期 11, 页码 1821-1829出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddab364
关键词
-
资金
- National Institutes of Health [NIAMS P50AR065139, NINDS U01NS101944]
- MDA Clinical Research Network Grant [573783]
- FSH Society Grant [52016]
- Friends of FSH Research
- Chris Carinno Foundation
Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to the development of therapeutic approaches and the need for biomarkers of disease activity and progression. This study found elevated complement components in plasma from FSHD patients, suggesting the potential use of complement activation measurements as a non-invasive assessment of FSHD disease activity, progression, and response to therapies.
Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to several therapeutic approaches entering clinical trials and an increased need to develop biomarkers of disease activity and progression. Multiple prior studies have shown early elevation of RNAs encoding components of the complement pathways and relatively widespread activated complement complexes by immunodetection in FSHD muscle. The current study tested plasma from two independent cohorts of FSHD and control subjects and found elevated complement components in both FSHD cohorts. Combining subjects from both cohorts identified complement factors that best distinguished FSHD and controls. Within the FSHD group, a subset of subjects showed elevation in multiple complement components. Together these findings suggest the need for future studies to determine whether measurements of complement activation can be used as a non-invasive measurement of FSHD disease activity, progression and/or response to therapies. In addition, with the ongoing expansion of complement therapeutic approaches, consideration for precision-based targeting of this pathway is appropriate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据